US panel gives mixed vote to Protein Sciences' cell-based flu vaccine FluBlok
This article was originally published in Scrip
Protein Sciences' novel trivalent seasonal influenza vaccine FluBlok (purified recombinant influenza haemagglutinin) is effective in subjects up to age of 49 years but not in older populations, and data do not support the cell-based vaccine's safety in all adults, the US FDA's experts have said.
You may also be interested in...
Given the rarity of epithelioid sarcoma, ‘the possibility exists that this trial will not be completed,’ Division of Oncology 3 acting director Steven Lemery said in recommending approval; confirmatory trial is not expected to complete until 2029, and FDA reviewers suggest it may be underpowered to show an effect on progression-free survival. (Part 2 of our Drug Review Profile on the product.)
Chronicle of the development and review of Epizyme’s epithelioid sarcoma treatment tazemetostat.
US FDA reviewers recommended against accelerated approval of Epizyme’s tazemetostat for epithelioid sarcoma, finding the modest overall response rates were not substantial evidence of an improvement over available therapies; they were overruled by senior oncology review staff, who cited a unanimous ODAC endorsement and the regulatory flexibility encouraged for rare diseases.